MCID: HYP066
MIFTS: 63

Hyperglycemia

Categories: Blood diseases, Metabolic diseases

Aliases & Classifications for Hyperglycemia

MalaCards integrated aliases for Hyperglycemia:

Name: Hyperglycemia 12 75 29 55 6 43 44 15 72

Classifications:



External Ids:

Disease Ontology 12 DOID:4195
MeSH 44 D006943
NCIt 50 C26797
SNOMED-CT 68 80394007
ICD10 33 R73.9
UMLS 72 C0020456

Summaries for Hyperglycemia

MedlinePlus : 43 Hyperglycemia means high blood sugar or glucose. Glucose comes from the foods you eat. Insulin is a hormone that moves glucose into your cells to give them energy. Hyperglycemia happens when your body doesn't make enough insulin or can't use it the right way. People with diabetes can get hyperglycemia from not eating the right foods or not taking medicines correctly. Other problems that can raise blood sugar include infections, certain medicines, hormone imbalances, or severe illnesses.

MalaCards based summary : Hyperglycemia is related to diabetes mellitus, permanent neonatal and maturity-onset diabetes of the young, type 2, and has symptoms including seizures, fever and dyspnea. An important gene associated with Hyperglycemia is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Developmental Biology and Aldosterone synthesis and secretion. The drugs Pancrelipase and Lixisenatide have been mentioned in the context of this disorder. Affiliated tissues include endothelial, liver and brain, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 75 Hyperglycemia (also spelled hyperglycaemia or hyperglycamia), is a condition in which an excessive... more...

Related Diseases for Hyperglycemia

Diseases related to Hyperglycemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 817)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus, permanent neonatal 33.4 PDX1 KCNJ11 INS GCK ABCC8
2 maturity-onset diabetes of the young, type 2 33.3 PDX1 INS HNF1A GCK
3 microvascular complications of diabetes 1 32.9 SST INS IGF1 AKR1B1
4 diabetes mellitus, transient neonatal, 1 32.9 KCNJ11 INS ABCC8
5 hyperinsulinism 32.2 SST LEP KCNJ11 INSR INS IGF1
6 diabetes mellitus, insulin-dependent 32.1 SST INS IGF1 IAPP HNF1A GCK
7 hypoglycemia 32.1 KCNJ11 INSR INS GCK GCG ABCC8
8 microvascular complications of diabetes 5 31.7 INS IGF1 ALB AKR1B1
9 lipid metabolism disorder 31.6 PPARG LEP INS ADIPOQ
10 microvascular complications of diabetes 3 31.5 MALAT1 INS ALB
11 vascular disease 31.4 PPARG INS ALB ADIPOQ
12 fatty liver disease, nonalcoholic 1 31.4 LEP INS ADIPOQ
13 atherosclerosis susceptibility 31.4 PPARG INS ADIPOQ
14 diabetic neuropathy 31.3 LEP INS AKR1B1
15 retinal vascular disease 31.2 INS ALB AKR1B1
16 peripheral nervous system disease 31.1 INS ALB AKR1B1
17 acute insulin response 31.1 KCNJ11 INS GCG ABCC8
18 autonomic neuropathy 31.1 INS ALB AKR1B1
19 acromegaly 31.1 SST INS IGF1
20 gestational diabetes 31.0 LEP KCNJ11 INSR INS IAPP GCK
21 hyperandrogenism 30.8 INSR INS IGF1
22 liver disease 30.8 LEP INS ALB ADIPOQ
23 proteasome-associated autoinflammatory syndrome 1 30.7 PPARG INS ALB ADIPOQ
24 polycystic ovary syndrome 30.7 LEP INSR INS IGF1
25 hirata disease 30.6 INS GCG ABCC8
26 insulin-like growth factor i 30.6 SST LEP INSR INS IGF1
27 fanconi-bickel syndrome 30.6 SLC2A2 INS ABCC8
28 sleep apnea 30.6 LEP INS IGF1 ADIPOQ
29 arteries, anomalies of 30.5 PPARG LEP INS ALB ADIPOQ
30 glucose intolerance 30.5 PPARG LEP INSR INS IGF1 GCK
31 dumping syndrome 30.5 SST INS GCG
32 maturity-onset diabetes of the young, type 3 30.5 PDX1 INS HNF1A GCK
33 uremia 30.5 LEP INS ALB
34 donohue syndrome 30.5 INSR INS IGF1
35 fatty liver disease 30.4 MALAT1 LEP INSR INS ADIPOQ
36 monogenic diabetes 30.4 PDX1 KCNJ11 INS HNF1A GCK ABCC8
37 islet cell tumor 30.4 SST INS IAPP
38 abdominal obesity-metabolic syndrome 1 30.4 PPARG LEP INS ADIPOQ
39 renal cysts and diabetes syndrome 30.3 PDX1 HNF1A GCK
40 hyperthyroidism 30.3 SST LEP INS
41 hyperinsulinemic hypoglycemia 30.3 SST KCNJ11 INSR INS GCK ABCC8
42 neonatal diabetes mellitus 30.2 SLC2A2 PDX1 KCNJ11 INS GCK ABCC8
43 gastrointestinal system disease 30.2 SST INS GCG ALB
44 hypertension, essential 30.2 LEP INSR INS ALB ADIPOQ
45 pancreatic agenesis 30.1 PDX1 KCNJ11 INS GCK ABCC8
46 overnutrition 30.1 PPARG LEP INS IGF1 GCG ADIPOQ
47 insulinoma 30.1 SST SLC2A2 PDX1 INS IAPP GCK
48 prediabetes syndrome 30.0 PPARG LEP INS GCG DPP4 ALB
49 fetal macrosomia 30.0 LEP INSR INS IGF1
50 liver cirrhosis 29.9 SST MALAT1 LEP ALB ADIPOQ

Graphical network of the top 20 diseases related to Hyperglycemia:



Diseases related to Hyperglycemia

Symptoms & Phenotypes for Hyperglycemia

UMLS symptoms related to Hyperglycemia:


seizures, fever, dyspnea, edema, cachexia, vertigo, headache, syncope, cyanosis, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes, symptoms

MGI Mouse Phenotypes related to Hyperglycemia:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 ABCC8 ADIPOQ AKR1B1 ALB DPP4 GCK
2 growth/size/body region MP:0005378 10.36 ADIPOQ AKR1B1 DPP4 GCK HNF1A IAPP
3 endocrine/exocrine gland MP:0005379 10.32 ABCC8 ADIPOQ ALB DPP4 GCK HNF1A
4 behavior/neurological MP:0005386 10.25 ADIPOQ AKR1B1 HNF1A INS INSR KCNJ11
5 adipose tissue MP:0005375 10.18 ADIPOQ HNF1A IGF1 INS INSR KCNJ11
6 mortality/aging MP:0010768 10.17 ADIPOQ AKR1B1 ALB GCK HNF1A IGF1
7 digestive/alimentary MP:0005381 10.1 ALB HNF1A INS INSR LEP PDX1
8 liver/biliary system MP:0005370 10.07 ADIPOQ ALB GCK HNF1A INS INSR
9 integument MP:0010771 10.01 ADIPOQ HNF1A IGF1 INS KCNJ11 LEP
10 muscle MP:0005369 10 ADIPOQ ALB HNF1A IGF1 INS INSR
11 renal/urinary system MP:0005367 9.73 ADIPOQ AKR1B1 ALB GCK HNF1A IGF1
12 no phenotypic analysis MP:0003012 9.7 ABCC8 HNF1A INS KCNJ11 PDX1 PPARG
13 skeleton MP:0005390 9.32 ADIPOQ AKR1B1 HNF1A IAPP IGF1 INS

Drugs & Therapeutics for Hyperglycemia

Drugs for Hyperglycemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 772)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4 53608-75-6
2
Lixisenatide Approved Phase 4 320367-13-3
3
Parecoxib Approved Phase 4 198470-84-7
4
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
5
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
6
Cobicistat Approved Phase 4 1004316-88-4
7
Rilpivirine Approved Phase 4 500287-72-9
8
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
9
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
10
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
11
Gliclazide Approved Phase 4 21187-98-4 3475
12
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
13
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
14
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
15
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
16
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
17
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
18
Nitric Oxide Approved Phase 4 10102-43-9 145068
19
Simvastatin Approved Phase 4 79902-63-9 54454
20
Remifentanil Approved Phase 4 132875-61-7 60815
21
Glimepiride Approved Phase 4 93479-97-1 3476
22
Pramlintide Approved, Investigational Phase 4 151126-32-8
23
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
24
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
25
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
26
Ziprasidone Approved Phase 4 146939-27-7 60854
27
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
28
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
29
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
30
Febuxostat Approved Phase 4 144060-53-7 134018
31
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
32
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
33
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
34
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
35
Enalaprilat Approved Phase 4 76420-72-9 6917719
36
Atenolol Approved Phase 4 29122-68-7 2249
37
Clozapine Approved Phase 4 5786-21-0 2818
38
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
39
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
40
Cetirizine Approved Phase 4 83881-51-0 2678
41
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
42
Mycophenolic acid Approved Phase 4 24280-93-1 446541
43
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
44
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
45
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
46
Cefpirome Approved Phase 4 84957-29-9 5479539
47
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
48
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
49
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
50
Polyestradiol phosphate Approved Phase 4 28014-46-2

Interventional clinical trials:

(show top 50) (show all 1626)
# Name Status NCT ID Phase Drugs
1 Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes: The FIT Study Unknown status NCT03057470 Phase 4 50% bolus insulin correction;100% bolus insulin correction;150% bolus insulin correction
2 ß-Cell Function and Glycemic Control of Basal Insulin, Metformin or Sitagliptin in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia Unknown status NCT01717911 Phase 4 Insulin;Metformin;Sitagliptin
3 A Pilot Study of Outpatient Discharge Therapy With Saxagliptin + Metformin XR or Sulphonylurea for Recently Diagnosed Type 2 Diabetes Presenting With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
4 Basal-bolus Insulin Therapy With Insulin Degludec and Insulin Aspart Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study Unknown status NCT03244241 Phase 4 Insulin Degludec 100 UNT/ML [Tresiba]
5 The Therapeutic Effects of Combination of Insulin With Berberine on the Patients With Stess Hyperlipemia:a Prospective, Double Blind, Randomized, Placebo-controlled, Single-center Clinical Trial Unknown status NCT02806999 Phase 4 Berberine; Insulin;Insulin
6 Randomized Controlled Clinical Study of Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury Unknown status NCT02161055 Phase 4 Insulin
7 Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin Unknown status NCT03195153 Phase 4 Atorvastatin 80mg;ALLOPURINOL 300 MG;Atorvastatin 80mg AND allopurinol 300 mg
8 A Prospective, Multi-center, Randomized, Controlled Study to Evaluate the Effect of DiPeptidyl-Peptidase 4 Inhibitor on Vascular Healing After Biodegradable Polymer Based Sirolimus Eluting Stent Implantation in Diabetic Patients: OCT Study (DIAMOND-OCT) Unknown status NCT02802644 Phase 4 Sitagliptin;Non DPP-4 Inhibitor
9 Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
10 Multiple Substitution of First Phase Insulin Response With a Rapid Action Insuli Analogue in Patient With Newly Diagnosed Type 2 Diabtes. Unknown status NCT00254085 Phase 4 Insulin Aspart
11 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
12 An Open-label, Randomized, Active-controlled Study to Compare the Effect of DPP-IV Inhibitor and TZD as add-on Therapy to Metformin on Glycemic Variability and Oxidative Stress in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy Unknown status NCT01339143 Phase 4 Galvus (vildagliptin);pioglitazone
13 The Effects of Short-Term Exenatide Therapy on the Beta-Cell Function and Long-term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients Unknown status NCT01270191 Phase 4 Exenatide;Humulin-N
14 A Randomized Controlled Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU Unknown status NCT02491346 Phase 4
15 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
16 To Compare the Efficacy and Safety Between Pioglitazone Added to Combination Therapy of Sulfonylurea Plus Metformin and Placebo Control Group in Patients With Type 2 Diabetes Unknown status NCT00991055 Phase 4 Pioglitazone
17 Antiatherogenic and Antimetabolic Effect of Curcumin in Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin
18 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
19 Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
20 Randomised Clinical Trial to Evaluate the Obtention of Blood Samples Through an Arterial Catheter to Monitor Glycose Levels Unknown status NCT01176279 Phase 4
21 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance, Tramadol PCA and Early Postoperative Enteral Nutrition in Patients After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
22 The Effect of Insulin Infusion on Metabolic Control and Inflammation in Diabetic Patients During Cardio-vascular Intervention and/or Treatment for Acute Foot Ulcer Infection. Unknown status NCT00700154 Phase 4
23 Treatment by Subcutaneous Continuous Infusion of Insulin by Portable Pump Versus Discontinuous Infusion of Insulin by Multi-injections in the Type 2 Diabetes: Study of the Insulinosensibility in the 2 Types of Treatments Unknown status NCT01889914 Phase 4 2 different procedures of administration of insulin
24 Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity (FLAME-study) Unknown status NCT01736202 Phase 4
25 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
26 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
27 Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy Unknown status NCT03112538 Phase 4 Multiple daily injections of insulin
28 The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men Unknown status NCT03002675 Phase 4 Bydureon
29 Type 2 Diabetes Mellitus: Role of Inflammation and Innate Immunity in The Pathogenesis of Endothelial Dysfunction and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
30 A Randomized Evaluation of the Effects of Valsartan and Aliskiren in Combination Versus Tekturna Alone on Hemostatic Biomarkers in Patients With Newly Diagnosed Mild to Moderate Hypertension and Type 2 Diabetes Mellitus Unknown status NCT01095822 Phase 4 Aliskiren + Valsartan
31 Long-term Sulfonylurea Response and Glucose Control After Switching From Insulin in Children With Diabetes Due to ABCC8 (SUR1) Mutations Unknown status NCT02624830 Phase 4 Sulfonylurea
32 The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) Unknown status NCT02501850 Phase 4 Liraglutide;metformin
33 A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT) Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
34 Evaluation of High-dose Corticosteroids on Microcirculation Alterations in Cardiac Surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and Biological Analysis (Syndecan-1) Unknown status NCT02798068 Phase 4 Solu-medrol or placebo administration
35 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
36 Randomized, Open Prospective Study of the Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 Unknown status NCT02719756 Phase 4 Metformin;Dapagliflozin;Metformin up-titration
37 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus. Unknown status NCT02011620 Phase 4
38 Absorption and Utilization of a Mixed Meal in Type 1 Diabetes: Creation of a Biological and In Silico Biobank for the Optimization of Artificial Pancreas Systems. A Pilot Study. Unknown status NCT01800734 Phase 4
39 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
40 Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin. Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
41 Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia Completed NCT01184014 Phase 4 NPH insulin plus Complete Insulin Orders;Complete Insulin Orders
42 Hyperglycemia and Effects of Daily 100 Milligrams Versus 200 Milligrams of Hydrocortisone Therapy in Patients With Septic Shock: A Double-Blind Randomized Controlled Trial Completed NCT02266264 Phase 4 Hydrocortisone
43 Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation Completed NCT00779701 Phase 4 Insulin
44 The Effect of Postprandial Hyperglycemia on the Arterial Stiffness in Patients With Type 2 Diabetes Completed NCT01159938 Phase 4 Lispro
45 Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia Completed NCT00362778 Phase 4 Insulin
46 Post Marketing Clinical Study of Aripiprazole in Patients With Schizophrenia - Effects on Glucose Metabolism- Completed NCT00392197 Phase 4 Aripiprazole
47 Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy Completed NCT02155374 Phase 4 Sliding scale insulin;Intermediate acting insulin;Glucose lowering medication;Chemotherapy
48 The Effect of Insulin Glargine on Glycemic Control, Morbidity, and Length of Stay in Hospitalized Subjects With Diabetes Receiving Enteral Nutrition Completed NCT00177398 Phase 4 Glargine insulin vs regular insulin
49 Glycemic Index Variation During Low-carbohydrate Enteral Formula With and Without Fructose in Critically Ill Patients: A Cross-over Randomized Clinical Trial Completed NCT03003507 Phase 4
50 A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia Completed NCT01239004 Phase 4 Placebo;Colesevelam

Search NIH Clinical Center for Hyperglycemia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Glycyrrhizic acid
Insulin
insulin beef, isophane
insulin beef-pork, isophane
insulin degludec
Insulin glargine
Insulin Glargine
insulin human, isophane
Insulin Lispro
Insulin Lispro
insulin pork, isophane
Insulin, Aspart Protamine, Human
Insulin, Aspart, Human
Insulin, Glulisine, Human
Insulin, Prompt Zinc, Beef
Insulin, Prompt Zinc, Beef-Pork
Insulin, Prompt Zinc, Pork
Insulin, Protamine Lispro, Human
insulin, protamine zinc, beef
Insulin, Protamine Zinc, Beef-Pork
Insulin, Protamine Zinc, Pork
Insulin, Regular, Beef
insulin, regular, beef-pork
Insulin, Regular, Pork
Insulin, Zinc, Human
Insulin, Zinc, Pork
INSULIN,DETEMIR,HUMAN
INSULIN,REGULAR,HUMAN BUFFERED
Lente Insulin, Beef
Lente Insulin, Beef-Pork
Mifepristone
Regular Insulin, Human
Ultralente Insulin, Beef
Ultralente Insulin, Beef-Pork
Ultralente Insulin, Human

Cochrane evidence based reviews: hyperglycemia

Genetic Tests for Hyperglycemia

Genetic tests related to Hyperglycemia:

# Genetic test Affiliating Genes
1 Hyperglycemia 29

Anatomical Context for Hyperglycemia

MalaCards organs/tissues related to Hyperglycemia:

41
Endothelial, Liver, Brain, Kidney, Heart, Pancreas, Testes

Publications for Hyperglycemia

Articles related to Hyperglycemia:

(show top 50) (show all 30395)
# Title Authors PMID Year
1
Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial. 38 17
31334795 2019
2
Risk factors and impact of postoperative hyperglycemia in nondiabetic patients after cardiac surgery: A prospective study. 38 17
31169705 2019
3
Glucose Metabolism Abnormalities in Heart Failure Patients: Insights and Prognostic Relevance. 17
31079691 2019
4
Enhanced proliferation and migration of vascular smooth muscle cells in response to vascular injury under hyperglycemic conditions is controlled by beta3 integrin signaling. 9 38
20184965 2010
5
Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients. 9 38
20207828 2010
6
Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system. 9 38
20197503 2010
7
C-reactive protein -717C>T genetic polymorphism associates with esophagectomy-induced stress hyperglycemia. 9 38
20145925 2010
8
[Endothelial dysfunction in diabetes]. 9 38
20446576 2010
9
Insulin-like growth factor-I-stimulated insulin receptor substrate-1 negatively regulates Src homology 2 domain-containing protein-tyrosine phosphatase substrate-1 function in vascular smooth muscle cells. 9 38
20207740 2010
10
Hyperglycemia and hypoxia are interrelated in their teratogenic mechanism: studies on cultured rat embryos. 9 38
20127827 2010
11
The effect of insulin signaling on female reproductive function independent of adiposity and hyperglycemia. 9 38
20176725 2010
12
Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors. 9 38
20425568 2010
13
Bone marrow transplantation temporarily improves pancreatic function in streptozotocin-induced diabetes: potential involvement of very small embryonic-like cells. 9 38
20110858 2010
14
Glucagon-like peptide-1 response to meals and post-prandial hyperglycemia in Type 2 diabetic patients. 9 38
19783893 2010
15
Hyperglycemia adversely modulates endothelial nitric oxide synthase during anesthetic preconditioning through tetrahydrobiopterin- and heat shock protein 90-mediated mechanisms. 9 38
20124983 2010
16
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. 9 38
20448799 2010
17
The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. 9 38
20299674 2010
18
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. 9 38
20222801 2010
19
Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. 9 38
19968982 2010
20
Addressing hyperglycemia from hospital admission to discharge. 9 38
20078323 2010
21
Heterocyclic indazole derivatives as SGK1 inhibitors, WO2008138448. 9 38
20021289 2010
22
Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes. 9 38
19923796 2010
23
Acute hyperglycemia produces transient improvement in glucose transporter type 1 deficiency. 9 38
20186957 2010
24
Protective effects of grape seed proanthocyanidin extracts on cerebral cortex of streptozotocin-induced diabetic rats through modulating AGEs/RAGE/NF-kappaB pathway. 9 38
20495289 2010
25
Pdx1-transfected adipose tissue-derived stem cells differentiate into insulin-producing cells in vivo and reduce hyperglycemia in diabetic mice. 9 38
19757377 2010
26
Naturally occurring glucokinase mutations are associated with defects in posttranslational S-nitrosylation. 9 38
19934346 2010
27
Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. 9 38
19720878 2009
28
[Coactivators in energy metabolism: peroxisome proliferator-activated receptor-gamma coactivator 1 family]. 9 38
20078951 2009
29
Increased circulating IL-8 is associated with reduced IGF-1 and related to poor metabolic control in adolescents with type 1 diabetes mellitus. 9 38
19773182 2009
30
Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. 9 38
19945407 2009
31
"Blinding" of AMP-dependent kinase by methylglyoxal: a mechanism that allows perpetuation of hepatic insulin resistance? 9 38
19643547 2009
32
High glucose-induced oxidative stress alters estrogen effects on ERalpha and ERbeta in human endothelial cells: reversal by AMPK activator. 9 38
19635557 2009
33
Contribution of glucose tolerance and gender to cardiac adiposity. 9 38
19820028 2009
34
Low plasma adiponectin level, white blood cell count and Helicobacter pylori titre independently predict abnormal pancreatic beta-cell function. 9 38
19747747 2009
35
Targeting SGK1 in diabetes. 9 38
19764891 2009
36
Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. 9 38
19790256 2009
37
Foxo1 links hyperglycemia to LDL oxidation and endothelial nitric oxide synthase dysfunction in vascular endothelial cells. 9 38
19584310 2009
38
Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families. 9 38
19564454 2009
39
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. 9 38
19758106 2009
40
Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulation. 9 38
19647774 2009
41
Combined effects of hyperglycemic conditions and HIV-1 Nef: a potential model for induced HIV neuropathogenesis. 9 38
19878567 2009
42
Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. 9 38
19624560 2009
43
Hyperinsulinemia predicts survival in a hyperglycemic mouse model of critical illness. 9 38
19623043 2009
44
RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts. 9 38
19477910 2009
45
Mild fasting hyperglycemia in children: high rate of glucokinase mutations and some risk of developing type 1 diabetes mellitus. 9 38
19309449 2009
46
Exposure of human keratinocytes to ischemia, hyperglycemia and their combination induces oxidative stress via the enzymes inducible nitric oxide synthase and xanthine oxidase. 9 38
19539448 2009
47
Intestinal cholecystokinin controls glucose production through a neuronal network. 9 38
19656488 2009
48
Identification of a novel beta-cell glucokinase (GCK) promoter mutation (-71G>C) that modulates GCK gene expression through loss of allele-specific Sp1 binding causing mild fasting hyperglycemia in humans. 9 38
19411616 2009
49
PDX1 deficiency causes mitochondrial dysfunction and defective insulin secretion through TFAM suppression. 9 38
19656489 2009
50
Insulin receptor gene mutations in iranian patients with type II diabetes mellitus. 9 38
19688022 2009

Variations for Hyperglycemia

ClinVar genetic disease variations for Hyperglycemia:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 KLF11 NM_003597.5(KLF11): c.23G> A (p.Gly8Asp) single nucleotide variant Uncertain significance rs1553312826 2:10183866-10183866 2:10043739-10043739

Copy number variations for Hyperglycemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 44162 10 52900000 70600000 Copy number TFAM Hyperglycemia

Expression for Hyperglycemia

Search GEO for disease gene expression data for Hyperglycemia.

Pathways for Hyperglycemia

Pathways related to Hyperglycemia according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.41 SLC2A2 PPARG PDX1 LEP INS IAPP
2
Show member pathways
12.78 SLC2A2 PDX1 KCNJ11 INS GCK GCG
3
Show member pathways
12.37 PPARG LEP INSR INS IGF1 ADIPOQ
4
Show member pathways
12.35 SLC2A2 LEP INS GCK
5
Show member pathways
12.3 SLC2A2 KCNJ11 INS GCG ADIPOQ ABCC8
6 12.25 SLC5A2 PPARG PDX1 INSR INS HNF1A
7
Show member pathways
12.18 LEP INS IGF1 GCG DPP4
8
Show member pathways
12.09 PPARG INSR INS IGF1 ADIPOQ
9 12.02 SLC2A2 PDX1 INS IGF1 ALB
10 11.97 PPARG LEP INS IGF1 HNF1A ADIPOQ
11
Show member pathways
11.89 SLC2A2 PDX1 INSR INS HNF1A GCK
12
Show member pathways
11.85 SLC2A2 INSR INS
13 11.82 SLC2A2 GCK GCG
14 11.82 INSR INS IGF1
15
Show member pathways
11.78 SLC5A2 SLC2A2 GCK
16
Show member pathways
11.73 SLC2A2 PDX1 INS IAPP HNF1A GCK
17
Show member pathways
11.52 LEP GCG DPP4
18 11.48 LEP KCNJ11 ABCC8
19 11.45 LEP INSR INS
20 11.43 INSR INS IGF1
21 11.3 INSR INS IGF1
22
Show member pathways
11.26 SLC2A2 PDX1 KCNJ11 INSR INS HNF1A
23 11.2 SLC2A2 PDX1 KCNJ11 INS HNF1A GCK
24 11.11 PPARG LEP ADIPOQ
25 11.08 PPARG LEP INSR ADIPOQ
26 10.83 SLC2A2 INS

GO Terms for Hyperglycemia

Cellular components related to Hyperglycemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 SST LEP INS IGF1 IAPP GCG
2 extracellular space GO:0005615 9.28 SST LEP INS IGF1 IAPP GCG
3 inward rectifying potassium channel GO:0008282 8.96 KCNJ11 ABCC8

Biological processes related to Hyperglycemia according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 LEP IGF1 GCG ALB AKR1B1
2 response to drug GO:0042493 9.97 SST PPARG KCNJ11 ADIPOQ ABCC8
3 cellular protein metabolic process GO:0044267 9.93 INS IGF1 IAPP ALB
4 positive regulation of protein kinase B signaling GO:0051897 9.91 LEP INSR INS IAPP
5 carbohydrate metabolic process GO:0005975 9.85 SLC5A2 SLC2A2 INSR INS GCK AKR1B1
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.81 LEP INS IGF1
7 cellular response to insulin stimulus GO:0032869 9.8 PPARG INSR GCK ADIPOQ
8 positive regulation of MAPK cascade GO:0043410 9.8 LEP INSR INS